| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
37,490,000 |
| Market
Cap: |
26.24(K) |
| Last
Volume: |
125 |
Avg
Vol: |
35,949 |
| 52
Week Range: |
$0.0002 - $0.0044 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Affymax is a biopharmaceutical company in the process of restructuring operations. Co.'s U.S. Food and Drug Administration approved product, OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis, has been recalled. As a result of the voluntary recall of OMONTYS, all marketing activities were suspended and sales were ceased. Co. granted its collaboration partner, Takeda Pharmaceutical Company Limited, a license to OMONTYS.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Apax Europe V Gp Co.ltd |
10% Owner |
– – • |
2009-09-16 |
4 |
S |
$21.62 |
$1,223,670 |
I/I |
(56,599) |
1,031,355 |
|
- |
|
| Apax Managers Inc |
10% Owner |
– – • |
2009-09-14 |
4 |
S |
$21.00 |
$2,734,305 |
I/I |
(130,205) |
834,272 |
|
- |
|
| Apax Europe V Gp Co.ltd |
10% Owner |
– – • |
2009-09-14 |
4 |
S |
$21.00 |
$3,565,695 |
I/I |
(169,795) |
1,087,954 |
|
- |
|
| Apax Europe V Gp Co.ltd |
10% Owner |
– – • |
2009-09-11 |
4 |
S |
$21.00 |
$4,754,274 |
I/I |
(226,394) |
1,257,749 |
|
- |
|
| Apax Managers Inc |
10% Owner |
– – • |
2009-09-11 |
4 |
S |
$21.00 |
$3,645,726 |
I/I |
(173,606) |
964,477 |
|
- |
|
| Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2009-09-03 |
4 |
AS |
$22.00 |
$71,500 |
D/D |
(3,250) |
0 |
|
- |
|
| Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2009-09-03 |
4 |
OE |
$0.80 |
$2,600 |
D/D |
3,250 |
3,250 |
|
- |
|
| Apax Managers Inc |
10% Owner |
– – • |
2009-09-01 |
4 |
S |
$22.25 |
$2,897,061 |
I/I |
(130,205) |
1,138,083 |
|
- |
|
| Apax Europe V Gp Co.ltd |
10% Owner |
– – • |
2009-09-01 |
4 |
S |
$22.25 |
$3,777,939 |
I/I |
(169,795) |
1,484,143 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2009-09-01 |
4 |
AS |
$25.00 |
$163,875 |
D/D |
(6,555) |
0 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2009-09-01 |
4 |
OE |
$0.80 |
$5,244 |
D/D |
6,555 |
6,555 |
|
- |
|
| Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2009-09-01 |
4 |
AS |
$23.00 |
$721,660 |
D/D |
(30,000) |
0 |
|
- |
|
| Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2009-09-01 |
4 |
OE |
$0.80 |
$24,000 |
D/D |
30,000 |
30,000 |
|
- |
|
| Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2009-05-01 |
4 |
AS |
$17.46 |
$29,630 |
D/D |
(1,697) |
0 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2009-03-02 |
4 |
B |
$15.25 |
$9,946,996 |
I/I |
652,262 |
2,224,407 |
1.5 |
- |
|
| Duliege Anne-Marie |
Chief Medical Officer |
• – – |
2008-05-15 |
4 |
S |
$15.50 |
$16,089 |
D/D |
(1,038) |
0 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-12-03 |
4 |
S |
$25.00 |
$189,674 |
D/D |
(7,551) |
619 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-12-03 |
4 |
OE |
$0.80 |
$10,202 |
D/D |
7,551 |
8,170 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-12-03 |
4 |
AS |
$25.00 |
$204,767 |
D/D |
(8,163) |
0 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-12-03 |
4 |
OE |
$0.80 |
$6,530 |
D/D |
8,163 |
8,163 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-11-06 |
4 |
AS |
$27.50 |
$181,639 |
D/D |
(6,487) |
0 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-11-06 |
4 |
OE |
$0.80 |
$5,190 |
D/D |
6,487 |
6,487 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-11-05 |
4 |
AS |
$27.50 |
$47,375 |
D/D |
(1,676) |
0 |
|
- |
|
| Morris Arlene |
President and CEO |
• • – |
2007-11-05 |
4 |
OE |
$0.80 |
$1,341 |
D/D |
1,676 |
1,676 |
|
- |
|
| Naso Robert B |
EVP, Research and Development |
• – – |
2007-11-01 |
4 |
S |
$27.67 |
$212,831 |
D/D |
(7,551) |
619 |
|
- |
|
225 Records found
|
|
Page 7 of 9 |
|
|
